Diabetic nephropathy cases in the US, Japan, and five major EU markets will increase during 2015–35, with most cases in older diabetics.
By Nicola Leckenby, Epidemiologist
1 April 2016
I joined Datamonitor Healthcare as an Epidemiologist in 2015. Prior to this, I obtained an MSc (with Distinction) in Pub...
Read full bio
Diabetic nephropathy (DN) is caused by damage to small blood vessels which can cause the kidneys to be less efficient in their blood filtration role or to fail altogether. DN is a clinical syndrome characterized by albuminuria, decline in glomerular filtration rate, and elevated arterial blood pressure.
Datamonitor Healthcare estimates that in 2015, there were 20 million prevalent cases of DN in adults aged 20 years or older in the US, Japan, and five major EU markets (France, Germany, Italy, Spain, and the UK). Over 2015–35, Datamonitor Healthcare expects that prevalent DN cases will increase. Datamonitor Healthcare estimates that diabetics aged over 60 years comprised the largest proportion of prevalent DN cases in the US, Japan, and five major EU markets combined in 2015.
Figure: Prevalent cases of diabetic nephropathy in the US, Japan, and five major EU markets, by country, 2015–35
ACE inhibitors and ARBs are the primary drug classes recommended for the treatment of diabetic nephropathy
Angiotensin-converting enzyme (ACE) inhibitors and angiotensin II receptor blockers (ARBs) are the primary drug classes recommended for the treatment of diabetic nephropathy, as they have beneficial effects beyond their blood pressure-lowering capabilities.
There are several ACE inhibitors and ARBs approved for diabetic nephropathy, but treatment guidelines do not generally make a distinction between the different drugs in these classes or whether they are specifically approved for this indication or not.
Current drugs in the pipeline for diabetic nephropathy are being tested in addition to standard of care, so will not be competing against the marketed ACE inhibitors or ARBs.
Get your free demo today – simply fill out the form to the right.